Troxacitabine
Jump to navigation
Jump to search
This article relies largely or entirely on a single source. (August 2014) |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H11N3O4 |
Molar mass | 213.193 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.[1]
References
- ^ Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, et al. (January 2007). "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma". Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578. PMID 17325846. S2CID 36220728.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles needing additional references from August 2014
- All articles needing additional references
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Experimental cancer drugs
- All stub articles
- Pharmacology stubs